| Molecular Formula | C19H21NO4 |
| Molar Mass | 327.37 |
| Density | 1.2223 (rough estimate) |
| Melting Point | 184° (Lewenstein), 177-178° (Sankyo Co.) |
| Boling Point | 465.27°C (rough estimate) |
| Flash Point | 9℃ |
| pKa | pKa 7.94/7.82(H2O,t =20/37,I<0.01) (Uncertain) |
| Storage Condition | 2-8°C |
| Refractive Index | 1.5000 (estimate) |
| Physical and Chemical Properties | EPA Chemical Information Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5.alpha.)- (465-6) |
| Risk Codes | R11 - Highly Flammable R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed. R39/23/24/25 - |
| Safety Description | S7 - Keep container tightly closed. S16 - Keep away from sources of ignition. S36/37 - Wear suitable protective clothing and gloves. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
| UN IDs | UN1230 - class 3 - PG 2 - Methanol, solution |
| WGK Germany | 3 |
| HS Code | 2939190000 |
| Toxicity | An opiate antagonist devoid of agonist activity except for mild, specific effects at very high doses. Naloxone displays a high affinity for the μ-opioid receptor, a lesser affinity for the kopioid receptor and has some affinity for δ-opioid receptor subtypes. Naloxone produces a rapid and profound reversal of the effects of opioid administration (e.g., 1 mg, i.v., blocks the effects of 25 mg of heroin). Naloxone also antagonizes the analgesia induced by placebo, acupuncture, and stress, and in animals the hypotension due to hypovolemia or spinal cord injury. Naloxone has a short half-life (about 1 h in plasma) and is not administered orally because of rapid, “first-pass” metabolism. |